Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00152724
Recruitment Status : Completed
First Posted : September 9, 2005
Last Update Posted : November 1, 2017
Information provided by (Responsible Party):
University Hospital, Angers

Brief Summary:
Microvascular dysfunctions are critical events in several diseases including diabetes. This study will develop a methodology for microvascular investigation in human skin. The purpose of the study is to investigate the physiological response of the cutaneous microcirculation to physical, thermal, mechanical or chemical stimulations.

Condition or disease Intervention/treatment
Healthy Volunteers Device: pressure strain system, iontophoresis Drug: scopolamin Drug: emla Drug: capsaicin Drug: aspirin Drug: clopidogrel Drug: celecoxib Drug: indomethacin Drug: acetylcholine Drug: sodium nitroprusside Drug: brethyllium Device: general and local heating

Detailed Description:
This study has investigated various aspects of the physiology of the microcirculation in the past years and is still recruiting under parallel protocols of physiological investigations of the neurovascular control of the cutaneous microcirculation.

Study Type : Observational
Actual Enrollment : 85 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Etude de la Reserve Vasomotrice Microcirculatoire cutanée
Study Start Date : January 1996
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Primary Outcome Measures :
  1. Amplitude of the vasomotor response to stimuli [ Time Frame: 1 hour ]

Secondary Outcome Measures :
  1. Kinetics of the vasomotor response to stimuli [ Time Frame: 1 hour ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers with no clinical signs of, or risk factors for, vascular disease

Exclusion Criteria:

  • Smokers, Pregnancy, Allergy,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00152724

Laboratoire de Physiologie et Explorations Vasculaires - CHU Angers
Angers, France, 49033
Sponsors and Collaborators
University Hospital, Angers
Principal Investigator: Jean Louis SAUMET, MD - PhD University Hospital, Angers

Publications of Results:

Responsible Party: University Hospital, Angers Identifier: NCT00152724     History of Changes
Other Study ID Numbers: CP96-04
First Posted: September 9, 2005    Key Record Dates
Last Update Posted: November 1, 2017
Last Verified: March 2007

Keywords provided by University Hospital, Angers:
Laser-Doppler Flowmetry

Additional relevant MeSH terms:
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Dermatologic Agents
Gout Suppressants
Tocolytic Agents
Reproductive Control Agents
Vasodilator Agents